Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Phase 1
Active, not recruiting
- Conditions
- Prostatic NeoplasmsTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-503919-15-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Male
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method